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LETTERS TO THE EDITOR
Absence of Mutations
in the Epidermal
Growth Factor
Receptor (EGFR) Kinase
Domain in Patients
with Mesothelioma
To the Editor:
Malignant mesothelioma, a debili-
tating and often fatal malignancy occurs
most commonly in patients with a history
of exposure to asbestos. Majority of pa-
tients with pleural malignant mesotheli-
oma present with unresectable disease.
Epidermal Growth Factor Receptor
(EGFR) is one of erbB family of recep-
tor tyrosine kinases (TK) known to play
a critical role in the cell proliferation and
survival in malignant neoplasms. Sev-
eral studies have reported an increased
expression of EGFR in mesothelioma.
EGFR-expressing mesothelioma cell lines
seemed to be sensitive to treatment with
EGFR tyrosine kinase inhibitors.1
After these observations, the Can-
cer and Leukemia Study Group B con-
ducted a phase II trial of gefitinib, an
EGFR TK inhibitor in 43 previously
untreated patients with mesothelioma.2
Of the 28 samples tested for EGFR ex-
pression, 27 (97%) had an overexpres-
sion of EGFR. Despite EGFR overex-
pression, gefitinib was not active in
malignant mesothelioma. EGFR expres-
sion is not an independent prognostic
factor in patients with mesothelioma.2,3
There is a striking discordance between
EGFR expression and lack of response to
EGFR TK inhibitors in malignant me-
sothelioma. Mutations in exons 18–21 of
the EGFR are associated with response
to EGFR TK inhibitors in non-small cell
lung cancer. There are only limited data
on the prevalence of EGFR TK muta-
tions in mesothelioma.
We sought to investigate the pres-
ence of any EGFR mutations in our pa-
tients with mesothelioma. A total of 32
patients with a histologically confirmed
diagnosis of mesothelioma seen at the
Washington University School of Medi-
cine were included in this study. DNA
samples were obtained from paraffin-em-
bedded tissue blocks containing representa-
tive malignant cells. High-throughput (96-
well plate) bidirectional dideoxynucleotide
sequencing of polymerase chain reaction-
amplified gene products was performed at
the Genome Sequencing Center (Wash-
ington University in St. Louis) as per
standard protocol http://genome.wustl.
edu/activity/med_seq/protocols.cgi. Ex-
onic regions 18–21, including the
exon/intron boundaries of EGFR (Entrez
GeneID 2065) were amplified by poly-
merase chain reaction. The sequence
traces were assembled and scanned for
variations from the reference sequence
through the use of PolyPhred and Poly-
Scan. All detailed protocols and primer
sequences are available through the
Washington University School of Medi-
cine GSC website (http://genome.wustl.
edu/platforms.cgi?id7).
After sequencing the DNA from the
32 mesothelioma samples, we found no
evidence of mutations in our set of pa-
tients with mesothelioma. Our findings are
consistent with the three earlier published
studies.3–5 We further confirm the findings
that although increased expression of
EGFR is common in patients with me-
sothelioma, mutations of the EGFR kinase
region commonly occurring in non-small
cell lung cancer seem to be uncommon in
mesothelioma. Lack of activating muta-
tions in the EGFR TK domain may ex-
plain the inactivity of EGFR tyrosine ki-
nase inhibitors in mesothelioma.
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Carboplatin and
Weekly Paclitaxel for
the Treatment of
Advanced Non-small
Cell Lung Cancer
(NSCLC) During
Pregnancy
To the Editor:
Gestational lung cancer is a rare
disease, with less than 40 cases reported
in literature.1 Incidence is rising due to
current trends in delaying pregnancy
and increasing rates of smoking among
young women.2 Here we report a case of
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